C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
167/139, 195/1.1
C12N 5/18 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) C07K 16/30 (2006.01) A61K 38/00 (2006.01)
Patent
CA 1340587
A method of producing monoclonal antibodies that bind to human cancer-associated mucin-type glycoprotein antigens comprising: (1) immunizing a host with a core structure of a mucin-type glycoprotein; (2) fusing splenocytes from said immunized host with myeloma cells to form hybridoma cells; (3) culturing said hybridoma cells on selective medium; (4) selecting hybridoma cells surviving step (3) that secrete antibody that binds to said core structure of a mucin-type glycoprotein; (5) cloning said selected hybridoma cells from step (4); (6) culturing said cloned hybridoma cells; and (7) recovering said antibody. Hybridomas and monoclonal antibodies produced by the above-described method. Methods of passive and active immunization employing the monoclonal antibodies and mucin-type glycoproteins or synthetic oligosaccharide-carrier conjugates.
593376
Clausen Henrik
Hakomori Senitiroh
Kjeldsen Thomas J.
Singhal Anil
Takahashi Helio
Clausen Henrik
G. Ronald Bell & Associates
Hakomori Senitiroh
Kjeldsen Thomas J.
Singhal Anil
LandOfFree
Monoclonal antibodies and vaccine development directed to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies and vaccine development directed to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies and vaccine development directed to... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1205993